Summit Therapeutics is trading 4.82% higher at $18.14 on October 7, 2026, with no clear company-specific reason for the intraday gain identified in available search results. - Recent coverage highlighted AstraZeneca funding and a clinical-trial collaboration announced around October 2; neither establishes a direct reason for today’s move. - Major U.S. indexes are declining, which does not explain the stock’s gain. No same-direction sector catalyst or trading-volume detail was verified.